109347-40-2Relevant articles and documents
Synthesis of Arylacetaldehydes by Iridium-Catalyzed Arylation of Vinylene Carbonate with Arylboronic Acids
Wang, Zhe,Xue, Fei,Hayashi, Tamio
supporting information, p. 11054 - 11057 (2019/07/17)
The one-step synthesis of arylacetaldehydes by carbon–carbon bond formation between formylmethyl and aryl groups has been realized by the reaction of vinylene carbonate with arylboronic acids in the presence of an iridium/bisphosphine catalyst and a catalytic amount of tetrahydroxydiboron.
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4)inhibitors, compound profiling in cell-based target engagement assays
Le Bihan, Yann-Va?,Lanigan, Rachel M.,Atrash, Butrus,McLaughlin, Mark G.,Velupillai, Srikannathasan,Malcolm, Andrew G.,England, Katherine S.,Ruda, Gian Filippo,Mok, N. Yi,Tumber, Anthony,Tomlin, Kathy,Saville, Harry,Shehu, Erald,McAndrew, Craig,Carmichael, LeAnne,Bennett, James M.,Jeganathan, Fiona,Eve, Paul,Donovan, Adam,Hayes, Angela,Wood, Francesca,Raynaud, Florence I.,Fedorov, Oleg,Brennan, Paul E.,Burke, Rosemary,van Montfort, Rob L.M.,Rossanese, Olivia W.,Blagg, Julian,Bavetsias, Vassilios
supporting information, p. 316 - 337 (2019/06/05)
Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between
Compound with 2-aminopyrimidine structure as well as preparation method and purpose thereof
-
Paragraph 0104-0107, (2019/06/08)
The invention provides a compound of a 2-aminopyrimidine structure shown as a general formula (1), or a stereisomer, enantiomers or medically acceptable salt of the compound, a preparation method of the compound, a medicine composition containing the composition or a purpose of the composition. The compound shown as the general formula (1) can be used for preparing NIK kinase inhibitors, and can be used for preventing and/or treating diseases relevant to NIK kinase, particularly cancer and metabolic diseases, such as B-cell dysfunction related cancer such as multiple myeloma, lymphocyte carcinoma, diffuse large B cell lymphoma of liver cancer, hodgkin lymphoma and chronic lymphocytic leukemia, prostatic cancer, liver cancer, intestinal cancer, medicine induced liver damage, alcohol inducedliver damage, toxic induced acute liver injury, chronic liver inflammation and the like. The general formula (1) is shown in the description.